Call Us: 1.800.873.5297


FDA Issues Proposed Orders to Reclassify Transvaginal Mesh to a High-Risk Device

On April 29, 2014, the FDA issued an immediate release notifying the public of its issuance of two proposed orders to address risks associated with surgical mesh for transvaginal repair of pelvic organ prolapse (POP). If these orders are finalized, these orders will reclassify transvaginal mesh products from a moderate-risk device (Class II) to a high-risk device (Class III), thus requiring manufacturers to submit a premarket approval (PMA) application for the FDA to evaluate safety and effectiveness.

fdaWilliam Maisel, M.D., M.P.H. and Deputy Director of Science and Chief Scientist at the FDA’s Center for Devices and Radiological Health, said that “[t]he FDA has identified clear risks associated with surgical mesh for the transvaginal repair of pelvic organ prolapse and is now proposing to address those risks for more safe and effective products.” Maisel added, “If these proposals are finalized, we will require manufacturers to provide premarket clinical data to demonstrate a reasonable assurance of safety and effectiveness for surgical mesh used to treat transvaginal POP repair.”

Transvaginal mesh products (commonly referred to as pelvic mesh, vaginal mesh, or bladder slings) are medical devices that are surgically implanted in women to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). As a result of childbirth, hysterectomy, or menopause, a woman’s uterus, bladder or rectum may slip out of place due to weakened muscles or ligaments. As a result of these organs “dropping,” increased stress is placed on the woman’s vagina, causing pain and discomfort, as well as urinary incontinence in some cases. Although this is a sensitive condition, it impacts millions of women nationwide.

According to the most recent report released by the Judicial Panel on Multidistrict Litigation (JPML), over 30,000 transvaginal mesh lawsuits are pending in federal courts – and the number of cases continues to grow. Complications alleged to be associated with these transvaginal mesh products, include but are not limited to, erosion or perforation of the mesh product, pelvic or vaginal pain, dyspareunia, infection, urinary or bowel problems, mesh shrinkage or contraction, mesh migration and neuromuscular problems. Other alleged complications that women suffer from the use of transvaginal mesh include invasive surgeries, as well as costly and painful medical procedures, to remove the mesh and/or repair damage. Because the vaginal mesh/sling products are designed and placed with the intention of remaining in a woman permanently, they can be very difficult to remove and may require multiple surgeries.

On October 20, 2008, the FDA released a Public Health Notification concerning “Serious Complications Associated with Transvaginal Placement of Surgical Mesh in Repair of Pelvic Organ Prolapse and Stress Urinary Incontinence”. The purpose of this notification was to alert healthcare professionals that the FDA had received over 1,000 reports of complications associated with the mesh products. On July 13, 2011, the FDA released another FDA Safety Communication to health care professionals and patients involving the transvaginal mesh products placed for Pelvic Organ Prolapse. This updated Safety Communication states, “serious complications associated with surgical mesh for transvaginal repair of POP are not rare…Furthermore, it is not clear that transvaginal POP repair with mesh is more effective than traditional non-mesh repair in all patients with POP and it may expose patients to greater risk.”

If you or a loved one has suffered injuries after using the blood thinning medication Pradaxa®, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation. Schlichter, Bogard & Denton, LLP is a unique law firm that aggressively represents its clients injured as a result of dangerous pharmaceutical medications and unsafe medical devices. With hard work, creative thinking, and strong trial skills, we have earned an outstanding nationwide reputation by representing thousands of individuals who have suffered serious injuries.

Schlichter, Bogard & Denton, LLP also welcomes the opportunity to work with other attorneys on these types of cases. Schlichter, Bogard & Denton, LLP is available to either handle these cases or work as co-counsel, so other attorneys with Pradaxa® cases are invited to contact an attorney at the firm to explore this opportunity.


The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.